Table 6 Impact of mNGS on PCP patients’ antimicrobial therapy
Modififications(n [%]) | PCP patients (n = 17) % |
|---|---|
Remove agent | 8(47.0) |
Reduce antimicrobial spectrum | 4(23.5) |
Add agent | 5(29.4) |
Add TMP-SMZ | 14(82.4) |
Add caspofungin | 1(5.9) |
No change | 2(11.8) |